viously, he was Director of Cell Biology at Rigel Pharmaceuticals. Prior to that, Dr. Bennett served as an Assistant Professor in the Department of Molecular and Cell Biology at University of California, Berkeley
Eric Sjogren, Ph.D., Senior Vice President of Drug Discovery at Calithera, was most recently the Vice President and Head of Medicinal Chemistry at Roche, Palo Alto. He held a series of positions during his 15-year tenure at Roche. Prior to that, Dr. Sjogren was at Syntex for eight years.
Calithera's Board of Directors includes Susan Molineaux, Ph.D., Chris Christoffersen, Ph.D., Larry Lasky, Ph.D., from U.S. Venture Partners, Jean George from Advanced Technology Ventures, Deepa Pakianathan, Ph.D., from Delphi Ventures, and James Wells, Ph.D.
About Caspases in Cancer
The direct activation and targeting of caspases represents a novel approach to inducing apoptosis in cancer cells and may have utility across a broad range of cancer types while avoiding chemoresistance. Caspases are the proteases responsible for initiating apoptosis, or programmed cell death, in cancer cells. Cancer cells grow in an uncontrolled manner in part through their ability to develop mechanisms to resist apoptosis. Many classic cancer therapies (cytotoxic drugs and radiation therapy) work by inducing upstream pro-apoptotic pathways that then activate caspases to overcome this resistance.
About Calithera Biosciences
Calithera Biosciences was founded in 2010, witPage: 1 2 3 4 Related biology technology :1
. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure2
. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury3
. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix4
. YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer5
. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences6
. YM BioSciences raises US$3.2 million in support of JAK 1/2 program7
. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference8
. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab9
. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems10
. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology11
. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting